



(11) **EP 2 546 266 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
10.08.2016 Bulletin 2016/32

(45) Date of publication and mention
of the grant of the patent:
08.06.2016 Bulletin 2016/23

(21) Application number: **11753356.2**

(22) Date of filing: **08.03.2011**

(51) Int Cl.:
C07K 16/18 ^(2006.01) **A61K 39/395** ^(2006.01)
A61K 45/00 ^(2006.01) **A61K 49/00** ^(2006.01)
A61K 51/00 ^(2006.01) **A61P 9/00** ^(2006.01)
A61P 9/10 ^(2006.01) **A61P 35/00** ^(2006.01)
C12Q 1/02 ^(2006.01) **C12Q 1/68** ^(2006.01)
G01N 33/53 ^(2006.01) **A61P 1/16** ^(2006.01)
A61P 1/18 ^(2006.01) **A61P 21/00** ^(2006.01)
C12N 15/09 ^(2006.01)

(86) International application number:
PCT/JP2011/055365

(87) International publication number:
WO 2011/111698 (15.09.2011 Gazette 2011/37)

(54) **MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERP29 AND USE THEREOF**

MONOKLONALEN ANTIKÖRPER GEGEN DEN NEKROSEMARKER ERP29 SOWIE
VERWENDUNG DIESER MONOKLONALER ANTIKÖRPER

ANTICORPS MONOCLONAL ANTI-MARQUEUR DE NÉCROSE ERP29 ET SON UTILISATION

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **08.03.2010 JP 2010050106**

(43) Date of publication of application:
16.01.2013 Bulletin 2013/03

(83) **Declaration under Rule 32(1) EPC (expert
solution)**

(73) Proprietor: **FUJIFILM Corporation**
Tokyo 106-8620 (JP)

(72) Inventors:
• **SUGANO, Sumio**
Tokyo 108-8639 (JP)
• **KANZAKI, Yukari**
Tokyo 108-8639 (JP)
• **SAGA, Tsuneo**
Chiba-shi
Chiba 263-8555 (JP)

• **TSUJI, Atsushi**
Chiba-shi
Chiba 263-8555 (JP)

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(56) References cited:
EP-A2- 0 270 340 WO-A1-00/01822
WO-A1-03/016910 WO-A1-2007/085411
WO-A2-93/09437

• **BAMBANG I F ET AL: "Cytokeratin 19 regulates
endoplasmic reticulum stress and inhibits ERp29
expression via p38 MAPK/XBP-1 signaling in
breast cancer cells", EXPERIMENTAL CELL
RESEARCH, ACADEMIC PRESS, US, vol. 315, no.
11, 1 July 2009 (2009-07-01) , pages 1964-1974,
XP026140535, ISSN: 0014-4827, DOI:
10.1016/J.YEXCR.2009.02.017 [retrieved on
2009-03-02]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 546 266 B8

- **I FON BAMBANG ET AL:** "Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells", **LABORATORY INVESTIGATION**, vol. 89, no. 11, 21 September 2009 (2009-09-21), pages 1229-1242, XP055072073, ISSN: 0023-6837, DOI: 10.1038/labinvest.2009.87
- **DANMEI GAO ET AL:** "ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK", **LABORATORY INVESTIGATION**, vol. 92, no. 2, 7 November 2011 (2011-11-07), pages 200-213, XP055072069, ISSN: 0023-6837, DOI: 10.1038/labinvest.2011.163
- **CHANDRA H. ET AL.:** 'Proteome analysis of mouse macrophages treated with anthrax lethal toxin.' **BIOCHIMICA ET BIOPHYSICA ACTA (BBA) -PROTEINS & PROTEOMIC** vol. 1747, 2005, pages 151 - 159, XP027627689
- **ZHANG B. ET AL.:** 'ERp29 is a radiation-responsive gene in IEC-6 cell.' **JOURNAL OF RADIATION RESEARCH** vol. 49, 2008, pages 587 - 596
- **BAMBANG IF. ET AL.:** 'Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.' **LABORATORY INVESTIGATION** vol. 89, 2009, pages 1229 - 1242, XP055072073
- **ZHANG D ET AL:** "Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer", **INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY**, PERGAMON, GB, vol. 43, no. 1, 1 January 2011 (2011-01-01), pages 33-36, XP027559013, ISSN: 1357-2725 [retrieved on 2010-11-03]
- **Emily K Rainey-Barger ET AL:** "Dimerization of ERp29, a PDI-like Protein, Is Essential for Its Diverse Functions", **Molecular Biology of the Cell**, 1 April 2007 (2007-04-01), pages 1253-1260, XP055178779, DOI: 10.1091/mbc.E06 Retrieved from the Internet:
URL:<http://www.molbiolcell.org/content/18/4/1253.full.pdf> [retrieved on 2015-03-24]

专利名称(译)	抗坏死标记物erp29的单克隆抗体及其用途		
公开(公告)号	EP2546266B8	公开(公告)日	2016-08-10
申请号	EP2011753356	申请日	2011-03-08
[标]申请(专利权)人(译)	富士胶片株式会社		
申请(专利权)人(译)	富士胶片株式会社		
当前申请(专利权)人(译)	富士胶片株式会社		
[标]发明人	SUGANO SUMIO KANZAKI YUKARI SAGA TSUNEO TSUJI ATSUSHI		
发明人	SUGANO, SUMIO KANZAKI, YUKARI SAGA, TSUNEO TSUJI, ATSUSHI		
IPC分类号	C07K16/18 A61K39/395 A61K45/00 A61K49/00 A61K51/00 A61P9/00 A61P9/10 A61P35/00 C12Q1/02 C12Q1/68 G01N33/53 A61P1/16 A61P1/18 A61P21/00 C12N15/09		
CPC分类号	A61K51/1045 A61P1/16 A61P1/18 A61P9/00 A61P9/10 A61P21/00 A61P35/00 C07K16/18 C07K16/30 G01N33/574 G01N2800/00 A61K51/1093 C07K2317/14 C07K2317/76 C07K2317/92 G01N33/57496 G01N2333/47 G01N2333/908		
优先权	2010050106 2010-03-08 JP		
其他公开文献	EP2546266A4 EP2546266A1 EP2546266B1		
外部链接	Espacenet		

摘要(译)

[问题]提供针对生物标志物的单克隆抗体，其显示出高特异性，并且可以有效地用于检测和诊断与各种癌症和坏死病灶相关的各种病变，等等。

[平均]抗坏死标记物的单克隆抗体，其由以下氨基酸序列组成：(1) SEQ ID NO：1至3中任一个的氨基酸序列，或(2)具有取代，缺失和/或氨基酸序列的氨基酸序列在(1)的氨基酸序列中插入一个或几个氨基酸残基或与(1)的氨基酸序列具有90%或更高的同源性，并显示与氨基酸相同的功能，活性或性质(1)的酸序列作为蛋白质。